MedKoo product information:

Tigapotide

MedKoo Code#:  202921

Name:  Tigapotide

CAS#:  848084-83-3; 848084-84-4 (trifluoroacetic acid)   Synonym:   PCK3145. Chemical name: ***L-Threonine, L-α-glutamyl-L-tryptophyl-L-glutaminyl-L-threonyl-L-α-aspartyl-L-asparaginyl-S-[(acetylamino)methyl]-L-cysteinyl-L-α-glutamyl-L-threonyl-S-[(acetylamino)methyl]-L-cysteinyl-L-threonyl-S-[(acetylamino)methyl]-L-cysteinyl-L-tyrosyl-L-α-glutamyl-, mono(trifluoroacetate). ****L-α-glutamyl-L-tryptophyl-L-glutaminyl-L-threonyl-L-α-aspartyl-L-asparaginyl-S-[(acetylamino)methyl]-L-cysteinyl-L-α-glutamyl-L-threonyl-S-[(acetylamino)methyl]-L-cysteinyl-L-threonyl-S-[(acetylamino)methyl]-L-cysteinyl-L-tyrosyl-L-α-glutamyl-L-threonine mono(trifluoroacetate) 　 IUPAC/Chemical name:  L-alpha-glutamyl-L-tryptophyl-L-glutaminyl-L-threonyl-L-alpha-aspartyl-L-asparaginyl-S-[(acetylamino)methyl]-L-cysteinyl-L-alpha-glutamyl-L-threonyl-S-[(acetylamino)methyl]-L-cysteinyl-L-threonyl-S-[(acetylamino)methyl]-L-cysteinyl-L-tyrosyl-L-alpha-glutamyl-L-threonine trifluoroacetic acid

Chemical structure

Theoretical analysis

Tigapotide Chemical Formula: C82H119N21O34S3 Exact Mass: 2037.73904 Molecular Weight: 2039.14 m/z: 2037.73904 (100.0%), 2038.74240 (88.7%), 2039.74575 (38.8%), 2039.73484 (13.6%), 2040.73819 (12.0%), 2040.74911 (11.2%), 2038.73608 (7.8%), 2039.74329 (7.0%), 2039.73943 (6.9%), 2040.74664 (6.2%), 2041.74155 (5.3%), 2040.74279 (3.0%), 2041.75000 (2.7%), 2038.73843 (2.4%), 2041.75246 (2.4%), 2039.74178 (2.1%), 2042.74490 (1.5%), 2038.74532 (1.4%), 2038.74326 (1.3%), 2039.74867 (1.2%), 2039.74661 (1.1%), 2040.73187 (1.1%) Elemental Analysis: C, 48.30; H, 5.88; N, 14.42; O, 26.68; S, 4.72 Tigapotide trifluoroacetic acid Chemical Formula: C84H120F3N21O36S3 Molecular Weight: 2153.16 Elemental Analysis: C, 46.86; H, 5.62; F, 2.65; N, 13.66; O, 26.75; S, 4.47

Availability and price: This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

Quality control data: Product will be shipped with supporting analytical data.

PCK3145 is a synthetic 15-mer peptide corresponding to amino acids 31-45 of the 94-amino acid isoform of human prostate secretory protein (PSP-94) with potential anti-metastasis and anti-angiogenesis activities. PSP-94-derived peptide PCK3145 may inhibit the secretion of the metastasis-related protein matrix metalloproteinase-9 (MMP-9) and its potential binding to its cell surface receptor CD44; may interfere with the vascular endothelial growth factor (VEGF) signaling pathway, resulting in an anti-angiogenesis effect; and may reduce the levels of parathyroid hormone-related protein (PTHrP), decreasing plasma calcium levels. PSP-94, one of three predominant proteins found in seminal fluid, may be down-regulated in prostate cancer, representing a potential survival mechanism for prostate cancer cells. MMP-9 is implicated in the invasion and metastasis of cancer. PTHrP may be expressed by various tumor cell types, resulting in the hypercalcemia of malignancy. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Current developer:    Procycon Biopharma, Inc.

 1: Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun. 2006 Jul 21;346(1):358-66. Epub 2006 Jun 2. PubMed PMID: 16759641.

2: Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs. 2006 Apr;17(4):429-38. PubMed PMID: 16550001.

3: Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Annabi B. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer. 2006 May 1;118(9):2350-8. PubMed PMID: 16331603.

4: Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis. 2005;22(5):429-39. PubMed PMID: 16283486.

5: Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs. 2005 Nov;16(10):1045-51. Review. PubMed PMID: 16222145.

6: Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, Fenemore J, Irvine A, Sereda K, Dulude H. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer. 2005 Sep;4(2):91-9. PubMed PMID: 16197609.

7: Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res. 2004 Aug 1;64(15):5370-7. PubMed PMID: 15289344.